Thryv Therapeutics
Publications and Presentations
Our clinical and preclinical data sets presented at leading medical and scientific forums, alongside select reference publications from the broader scientific community, spanning Long QT Syndrome, heart failure, cardiometabolic disease and atrial fibrillation.
New in JACC: Heart Failure
Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure
Open access · September 2026
LATEST · AHA Scientific Sessions 2026
SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure
Late-breaking · November 7, 2026 · 2:30 PM to 3:30 PM
What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey
Poster · November 8, 2026 · 11:30 AM to 12:30 PM
Long QT Syndrome
PUBLICATIONS
May 2026
SGK1-inhibition restores cardiac repolarization in LQT2 rabbits and LQT3 mice by reducing late sodium current
Pharmacological Research
November 2025
SGK1 inhibition shortens action potential duration and exerts anti-arrhythmic effects in LQT3 mice and LQT2 rabbits by reducing enhanced late sodium current
European Heart Journal
May 2023
Gene and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2
EP Europace
April 2023
SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation
Heart Rhythm
February 2023
SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome
Heart Rhythm O2
PRESENTATIONS
November 2026
What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey
American Heart Association Scientific Sessions
April 2025
SGK-1 inhibition with LQT-1213 significantly reduces the QTcF in patients with congenital Long QT Syndrome in the Wave I, Part 2 study
Heart Rhythm Society Annual Meeting · San Diego, CA
November 2024
SGK1 inhibition shortens action potential duration in LQT3 mice and LQT2 rabbits via inhibition of late sodium current
American Heart Association Scientific Sessions · Chicago, IL
May 2024
Attenuation of drug-induced QT prolongation in guinea pig isolated heart and anesthetized dog models of drug-induced QT prolongation by serum/glucocorticoid regulated kinase 1 (SGK-1) inhibitors
Heart Rhythm Society Conference · Boston, MA
March 2024
SGK-1 inhibitor attenuates QTcF prolongation in a dofetilide-induced human model (Wave I clinical study)
American College of Cardiology Conference · Atlanta, GA
November 2022
SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital Long QT Syndrome
AHA Scientific Sessions · Chicago, IL
November 2022
SGK1 inhibition and attenuation of action potential duration in re-engineered heart cell models of drug-induced QT prolongation
AHA Scientific Sessions · Chicago, IL
REFERENCE PUBLICATIONS
November 2025
March 2017
Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders
Scientific Reports
June 2003
Modulating effects of age and gender on the clinical course of Long QT Syndrome by genotype
JACC Journals
May 2003
February 2000
Effectiveness and limitations of β-blocker therapy in congenital Long-QT Syndrome
Circulation
Heart Failure and Cardiomyopathies
PUBLICATIONS
September 2026
Genetic, preclinical, and clinical evidence supports SGK1 inhibition in heart failure
JACC: Heart Failure
November 2025
A novel serum glucocorticoid regulated kinase 1 inhibitor improves cardiac structure and function in heart failure (pre-print)
Sciety
PRESENTATIONS
November 2025
Small molecule inhibitors of serum glucocorticoid kinase 1 (SGK1) prevent cardiac structural and functional decline in a transverse aortic constriction (TAC) model
AHA Scientific Sessions · New Orleans, LA
November 2025
THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure
AHA Scientific Sessions · New Orleans, LA
November 2025
The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition
AHA Scientific Sessions · New Orleans, LA
August 2025
THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure
European Society of Cardiology (ESC) Congress · Madrid, Spain
November 2024
Serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor reduced hypertension in a salt-sensitive hypertension model of heart failure with preserved ejection fraction
AHA Scientific Sessions · Chicago, IL
November 2024
SGK1 inhibition attenuated left ventricular thickening and diastolic dysfunction in a mouse model of HFpEF
AHA Scientific Sessions · Chicago, IL
November 2024
Serum and glucocorticoid regulated kinase 1 (SGK1) inhibition induces anti-fibrotic and anti-inflammatory responses: relevance to cardiac fibrosis
AHA Scientific Sessions · Chicago, IL
REFERENCE PUBLICATIONS
January 2026
January 2026
One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge
JAMA Cardiology
October 2024
Serum and glucocorticoid-regulated kinase 1 (SGK1) as an emerging therapeutic target for cardiac diseases
Pharmacological Research
September 2023
New challenges in heart failure with reduced ejection fraction: managing worsening events
Journal of Clinical Medicine
October 2012
Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling
Circulation
April 2003
QTc interval and B-type natriuretic peptide levels predict death in patients with advanced heart failure
Circulation
Cardiometabolic disease
Presentations
November 2026
SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure
American Heart Association Scientific Sessions
July 2026
A Potent Serum and Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitor is Protective in a Model of CKMD
Basic Cardiovascular Sciences (BCVS) Scientific Sessions
Atrial Fibrillation
PRESENTATIONS
November 2023
A novel SGK1 inhibitor (SGK1-I) prevents obesity-related atrial fibrillation
American Heart Association Scientific Sessions · Philadelphia, PA
Reference publications
August 2022
Genetic inhibition of serum glucocorticoid kinase 1 prevents obesity-related atrial fibrillation
JCI Insight